William G. Wierda

1989–2025 年に発表

318
論文数
56,759
被引用数
127
h 指数
312
i10 指数

被引用数

William G. Wierda の年別被引用数1979 年: 被引用 1 件1990 年: 被引用 1 件1991 年: 被引用 1 件1992 年: 被引用 2 件1993 年: 被引用 1 件1994 年: 被引用 4 件1995 年: 被引用 1 件1996 年: 被引用 2 件1997 年: 被引用 3 件1998 年: 被引用 2 件1999 年: 被引用 6 件2000 年: 被引用 10 件2001 年: 被引用 11 件2002 年: 被引用 20 件2003 年: 被引用 48 件2004 年: 被引用 53 件2005 年: 被引用 47 件2006 年: 被引用 110 件2007 年: 被引用 155 件2008 年: 被引用 232 件2009 年: 被引用 310 件2010 年: 被引用 352 件2011 年: 被引用 321 件2012 年: 被引用 380 件2013 年: 被引用 378 件2014 年: 被引用 424 件2015 年: 被引用 526 件2016 年: 被引用 465 件2017 年: 被引用 560 件2018 年: 被引用 682 件2019 年: 被引用 1,884 件2020 年: 被引用 2,367 件2021 年: 被引用 2,520 件2022 年: 被引用 1,890 件2023 年: 被引用 1,380 件2024 年: 被引用 2,399 件2025 年: 被引用 1,133 件2026 年: 被引用 41 件1980〜1989 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,400 件、この内訳の 29.6%中国: 引用元論文 1,750 件、この内訳の 9.6%ドイツ: 引用元論文 1,267 件、この内訳の 6.9%イギリス: 引用元論文 1,111 件、この内訳の 6.1%イタリア: 引用元論文 1,078 件、この内訳の 5.9%フランス: 引用元論文 783 件、この内訳の 4.3%オーストラリア: 引用元論文 613 件、この内訳の 3.3%スペイン: 引用元論文 582 件、この内訳の 3.2%カナダ: 引用元論文 458 件、この内訳の 2.5%オランダ: 引用元論文 434 件、この内訳の 2.4%スイス: 引用元論文 379 件、この内訳の 2.1%スウェーデン: 引用元論文 303 件、この内訳の 1.7%
0%29.6%その他 22.4%

分野

  • Medicine73.2%
  • Biochemistry, Genetics and Molecular Biology17.1%
  • Immunology and Microbiology6.8%
  • Chemistry0.7%
  • Engineering0.4%
  • Computer Science0.4%
  • その他1.4%

トピック

  • CAR-T cell therapy research9.9%
  • Chronic Lymphocytic Leukemia Research9.5%
  • Lymphoma Diagnosis and Treatment7%
  • Immune Cell Function and Interaction4.2%
  • Acute Myeloid Leukemia Research4.2%
  • Chronic Myeloid Leukemia Treatments3.5%
  • その他61.7%

共著者

全論文

検索で開く
  1. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 2,139

  2. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    著者: , , , , , , , , , , , , , , , , , , - Nature Reviews Clinical Oncology 2017 被引用: 2,380

  3. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roch Houot - The Lancet 2021 被引用: 769

  4. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 1,884

  5. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charlotte Graham, Deborah Yallop, Agnieszka Jóźwik, Antonio Pagliuca, Ghulam Mufti, Piers Patten, Shireen Kassam, Stephen Devereux, Majid Kazmi, Kirsty Cuthill, Victoria Potter, Andrea Kühnl, Victoria Metaxa, Laarni Bonganay, Orla Stewart, Rose Ellard, Lorraine Catt, Jen Lewis, Farzin Farzaneh, Jackie Chappell, Alice Mason, Vicky Chu, Alan Dunlop, Adeel Saleem, Gary Cheung, Helena Munro, Elka Giemza, Waseem Qasim, Paul Veys, Oana Ciocârlie, Giovanna Lucchini, Danielle Pinner, Jan Chu, Persis Amrolia, Kanchan Rao, Robert Chiesa, Juliana Silva, Annette Hill, Maria Finch, Lindsey Young, Harvinder Hara, Sujith Samarasinghe, Anupama Rao, Ajay Vora, Anupama Rao, Christine Rivat, Clare Murphy, Gulrukh Ahsan, Rasha Said Shamsah, Jesmina James, Sarah Inglott, Gary Wright, Stuart Adams, Natalia Izotova, Nitin Jain, Marina Konopleva, William G. Wierda, Elias Jabbour, Hagop M. Kantarjian, Partow Kebrieai, Emily Jones, Kara McGee, Marcela V. Maus, Matthew J. Frigault, Jami Brown, Vesselina Toncheva, Keagan S. Casey, Hanno Hock, Meaghan A McKeown, Richard Mathews ほか 40 名 - The Lancet 2020 被引用: 360

  6. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 被引用: 612

  7. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amy S. Ruppert, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak - New England Journal of Medicine 2023 被引用: 217

  8. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet 2023 被引用: 198

  9. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 被引用: 454

  10. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Donna Neuberg, J. Wade Harper, Steven A. Carr, Federica Piccioni, Christopher J. Ott, Ignaty Leshchiner, Cory M. Johannessen, John G. Doench, Vamsi K. Mootha, Gad Getz, Catherine J. Wu - Cancer Cell 2019 被引用: 360

  11. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 被引用: 2,249

  12. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

    著者: , , , , , , , , , , , , , , , , , , , - Blood 2022 被引用: 238

  13. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

    著者: , , , , , , , , , , , , - Leukemia 2021 被引用: 181

  14. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vicky Chu, Kirsty Cuthill, Steven Devereux, Alan Dunlop, Rose Ellard, Farzin Farzeneh, Najeem Folarin, Elka Giemza, Shireen Kassam, Majid Kazmi, Andrea Kühnl, Jen Lewis, M.Yu. Liskova, Alice Mason, Victoria Metaxa, Ghulam Mufti, Helena Munro, Antonio Pagliuca, Piers Patten, Victoria Potter, Carmel Rice, Adeel Saleem, Robin Sanderson, Orla Stewart, Elias Jabbour, Nitin Jain, Emily Jones, Hagop M. Kantarjian, Partow Kebriaei, Marina Konopleva, Kara McGee, William G. Wierda, Jami Brown, Keagan S. Casey, Matthew J. Frigault, Hanno Hock, Richard Mathews, Marcela V. Maus, Meaghan A McKeown, Thomas R. Spitzer, Vesselina Toncheva, Élie Azoulay, Nicolas Boissel, Sophie Caillat‐Zucman, Karine Celli‐Lebras, Emmanuelle Clappier, Raphaël Itzykson, Jérôme Larghero, Étienne Lengliné, Isabelle Madelaine, Martine Meunier, Florence Rabian, Emmanuel Raffoux, Marie-Thérèse Tremorin, Agnès Bonnin, Éolia Brissot, Anne Daguenel-Nguyen, Rémy Duléry, Tounes Ledraa, Florent Malard, Clémence Mediavilla, Mohamad Mohty, Anne Vekhoff, Takanori Teshima, Koji Kato - The Lancet Haematology 2022 被引用: 136

  15. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 被引用: 200

  16. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2022 被引用: 200

  17. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 229

  18. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 818

  19. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hagop M. Kantarjian, Michael J. Keating, William G. Wierda, Kim‐Anh Do, David A. Largaespada, Dean A. Lee, Perry B. Hackett, Richard E. Champlin, Laurence J.N. Cooper - Journal of Clinical Investigation 2016 被引用: 504

  20. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 751

  21. Ibrutinib and Venetoclax for First-Line Treatment of CLL

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Varsha Gandhi, William G. Wierda - New England Journal of Medicine 2019 被引用: 504

  22. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2023 被引用: 103

  23. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 891

  24. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 796